Latest Fingolimod Stories
The medication fingolimod reduced inflammatory lesion activity and reduced brain volume loss in patients with multiple sclerosis who participated in a two-year placebo-controlled clinical trial and were assessed by magnetic resonance imaging (MRI) measures.
Many of us have heard of or know someone with the dreadful disease known as multiple sclerosis. Affecting approximately 400,000 people in the United States and 2.5 million people worldwide, multiple sclerosis is still incurable and has few effective treatments available.
This report provides perspective on the MS landscape in light of Merck Seronoâ€™s decision to discontinue development and marketing of cladribine for MS. Scottsdale, AZ (PRWEB) June 27, 2011 MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report entitled â€œThought Leader Insight & Analysis: Multiple Sclerosis,â€ designed to provide critical strategic insight for pharma and biotech companies...
SILVER SPRING, Md., Sept. 22 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration has approved Gilenya capsules (fingolimod) to reduce relapses and delay disability progression in patients with relapsing forms of multiple sclerosis (MS).
EAST HANOVER, N.J., June 10 /PRNewswire/ -- Today, an advisory committee of the US Food and Drug Administration (FDA) recommended approval of FTY720 (fingolimod) for the treatment of patients with relapsing multiple sclerosis, the most common form of the disease.
- The act of sweetening by admixture of some saccharine substance.